The 50 mg dose some readers may remember belongs to the OASIS 1 trial (Knop et al., 2023), and is part of the wider evidence base rather than the approved product
We emphasize quality and safety by partnering only with certified providers
As medical science continues to evolve, weight loss treatments are becoming more accessible, safer, and more effective
Tirzepatide activates both GLP-1 and GIP receptors, producing somewhat different hunger patterns
Individual variationLike many supplements, L-carnitine weight loss effects may vary from person to person
This provides a solid rationale for considering a switch if maximizing weight loss is a key objective, particularly if results with semaglutide have plateaued